Minimal residual disease analysis in myeloma – when, why and where
- 11 October 2017
- journal article
- review article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 59 (8) , 1772-1784
Abstract
The primary hurdle in the path to curing multiple myeloma (MM) is defining a validated minimal residual disease (MRD) and its utility in the therapeutic decision making. A better definition of MRD will aid in tailoring MM therapy further to address the clonal heterogeneity and genomic instability and overcome patient’s ineffective immune surveillance. MRD analysis can define the logical endpoint for maintenance therapy, in addition also aids in providing a better clinical end point for studies comparing novel agents in myeloma. MRD is a surrogate for the survival in MM. Guidelines for global incorporation of MRD in myeloma are fraught with lack of standardization, universal availability and abridged physicians’ understanding of MRD modalities. We aimed at addressing some of the frequently asked questions in the MRD assessment and will also place in perspective some arguments in favor of MRD assessment in routine practice and clinical trial scenario.Keywords
Funding Information
- Celgene
- Millennium
- Novartis
- Onyx
- AbbVie
- Janssen
- BMS
This publication has 76 references indexed in Scilit:
- Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3Blood, 2013
- The Role of Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography in Evaluating the Response to Treatment in Patients with Multiple MyelomaInternational Journal of Molecular Imaging, 2012
- Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patientsLeukemia, 2012
- The genetic architecture of multiple myelomaNature Reviews Cancer, 2012
- Detection of a monoclonal antibody therapy (ofatumumab) by serum protein and immunofixation electrophoresisBritish Journal of Haematology, 2011
- An antibody-based biomarker discovery method by mass spectrometry sequencing of complementarity determining regionsAnalytical and Bioanalytical Chemistry, 2010
- Depth of response assessed by quantitative ASO‐PCR predicts the outcome after stem cell transplantation in multiple myelomaEuropean Journal of Haematology, 2010
- Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer SurvivalJournal of Clinical Oncology, 2008
- Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantationBlood, 2008
- International uniform response criteria for multiple myelomaLeukemia, 2006